New stock news | Boji Pharmaceutical's Hong Kong IPO prospectus invalidated

Shanghai Baoji Pharmaceutical Co., Ltd. (hereinafter referred to as Baoji Pharmaceutical) submitted its Hong Kong stock prospectus on January 21, which expired after 6 months on July 21, with CITIC SEC and HAITONG INT'L as joint sponsors at the time of submission. The prospectus shows that Baoji Pharmaceutical is a pioneer in China in developing and providing difficult-to-produce recombinant biopharmaceuticals using synthetic biotechnology to meet the clinical needs of a wide range of patients. Since its establishment in 2019, the company has focused on the research and development of large-scale biopharmaceuticals and aims to improve treatment standards by developing alternative biochemical products derived from animal organs, blood, or urine, or by upgrading existing treatment methods. Based on its unique chassis cell transformation technology and advanced drug design and biomanufacturing capabilities, Baoji Pharmaceutical has established a proprietary technology platform. This platform enables the company to take a leading position in the development of candidate drugs in four strategic therapeutic areas, with a combined potential market size of over 50 billion yuan by 2033, according to Frost & Sullivan: (i) high-capacity subcutaneous drug administration, (ii) antibody-mediated autoimmune diseases, (iii) assisted reproductive drugs, and (iv) transformative products replacing traditional biological products with recombinant biopharmaceuticals.